Bøger i Falk Symposium serien

The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease.

These proceedings of Falk Symposium 110 on `Intestinal Mucosa and its Diseases - Pathophysiology and Clinics' held at Titisee/Black Forest, Germany, 16-17 October 1998, comprehensively review salient clinical as well as scientific aspects - pending or settled - of the main intestinal diseases.

135 held in Prague, Czech Republic, on September 12-13, 2003, and is dedicated to the important issue of immunological aspects of diseases of the liver and gut. Without any doubt, immunological pathways are among the most important and universal factors in the pathogenesis of all diseases.

Although the first description of patients with what we now call Crohn's disease or ulcerative colitis was published well before 1900, both disorders seem to be diseases of the twentieth century.

Knowledge about the cell biology of the cholangiocytes and the function of the bile ducts has increased considerably. Their role in liver diseases is increasingly recognized. This work brings together scientists and clinicians to highlight the advances in molecular biology, physiology, diagnosis and therapy of diseases of the biliary system.

Pregnancy is the main determinant of some liver diseases in humans: acute fatty liver of pregnancy, cholestasis of pregnancy, and acute liver failure in toxaemia of pregnancy.

Presents an overview of the molecular pathology of liver disease. This book discusses the clinical inference which the scientific information entails for diagnosis, management and therapy.

Sections cover viral hepatitis, immunosuppressive approaches in liver patients, malignant liver diseases, inflammatory liver diseases and complications of liver cirrhosis.

Liver cirrhosis is a major clinical problem worldwide and is associated with significant morbidity and mortality from its complications, such as liver cell insufficiency with coagulopathy and hepatic encephalopathy, portal hypertension with ascites and gastrointestinal bleeding, hepatorenal syndrome, HCC development and others.

The Proceedings of Falk Symposium No. 116, held in Basel, Switzerland, October 25, 1999, (Part III of the Basel Liver Week 1999)

156 on Genetics in Liver Disease, part of the XIII International Liver Week 2006 held in Freiburg, Germany. In the tradition of the Falk Symposia, this book provides an exciting overview of current developments in the genetics of liver diseases, their diagnosis, treatment, and prevention.

Despite recent advances, the pathogenesis and therapy of various forms of chronic inflammatory diseases of the gastrointestinal tract remains problematical. and chronic inflammatory bowel diseases, particularly ulcerative colitis, are associated with an increased incidence of carcinoma.

The main focus of the book is to highlight the role of the immune system in gut and liver diseases and potential interactions of the gut and the liver respectively.

Covers the proceedings of the Falk Workshop on 'Strategies of Cancer Prevention in Gastroenterology', held in Mainz, Germany, on 17 September 2008. This book discusses various developments and challenges in cancer prevention in gastroenterology.

In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression.

In honour of Hans Popper's 100th birthday

In the era of evidence-based medicine it is often under debate whether evidence-based medicine may really improve the management of IBD patients or whether the diversity and complexity of IBD needs an individual and patient-oriented approach.

Features the proceedings of Falk Symposium 133 on Mechanisms of Intestinal Inflammation: Implications for Therapeutic Intervention in IBD', held in Berlin, Germany, on 10-11 June 2003. This book is useful for scientists and physicians, who have an interest in research on IBD and in the clinical management of these diseases.

In recent years, our knowledge about the pathogenesis, pathophysiology and treatment of hepatobiliary diseases has increased considerably.

Symposium in Honour of Gustav Paumgartner

Based on the proceedings of the Falk Symposium No 122 on "Inflammatory Bowel Disease - A Clinical Case Approach to Pathophysiology, Diagnosis, and Treatment", held in Bologna, Italy, on June 22-23, 2001. This book deals with issues concerning Genetics of IBD, Pediatrics in IBD, Early vs Late IBD, Bacteria and Gut Inflammation, and more.

The therapeutic handling of autoimmune liver disease is limited because basic mechanistic insights into immunologically mediated pathophysiology have not yet been translated into standard pharmacological treatments.

Based on lectures on the role of zinc in cell biology, the pathophysiology of zinc deficiency and consequently the possibilities of zinc substitution in these disorders is discussed.

It covers our present knowledge of the diagnosis, treatment and prevention of liver diseases, including hepatitis B, hepatitis C and delta hepatitis as well as alcoholic liver diseases, non-alcoholic steatohepatitis and the hereditary liver diseases haemochromatosis, Wilson's disease and alpha-1-antitrypsin deficiency.

Cancer chemotherapy frequently attacks the gastrointestinal tract. This book is the proceedings of the Falk Workshop 'Side-effects of Chemotherapy on the Gastrointestinal Tract: Pathogenesis and Therapy', held in Freiburg, Germany, on October 11, 2002 (Part IV of the Freiburg Gastroenterology Week).

Features the proceedings of Falk Symposium 130 on 'Gastrointestinal Inflammation and Disturbed Gut Function: The Challenge of New Concepts', held in Freiburg, Germany, on October 4-6, 2002. This book reviews work in the field and aims to stimulate research in the functional GI disorders.

Primary sclerosing cholangitis is a chronic disease of the intra- and extrahepatic bile ducts leading to obstructions and dilatations followed by liver cirrhosis and in some cases cholangiocarcinoma.

Cholestatic disorders of infancy and adulthood represent a major group of causes of end-stage chronic liver disease. There has been great scientific interest in these disorders in recent years, so the time has come to evaluate treatment modalities in old and even new cholestatic diseases.

The clinical efficacy of glucocorticoids in the treatment of inflammatory bowel disease has been confirmed in a multitude of controlled monocentre and multicentre studies as well as from observations of the clinical course of the disease.

Molecular diagnosis and gene therapy are of increasing interest and importance in clinical medicine. In this sense, the book should allow basic scientists as well as clinicians to be informed about the state-of-the-art of molecular diagnosis and gene therapy and should provide a perspective for future developments in molecular medicine.